Antibe testing confirms ATB-346 efficacy at lower doses

2015-04-17 07:50 ET - News Release

Mr. Dan Legault reports
ANTIBE THERAPEUTICS ANNOUNCES ADDITIONAL VALIDATION DATA ON ATB-346
Antibe Therapeutics Inc. released today the results of additional testing of the in vivo activity of its lead anti-inflammatory drug, ATB-346.

The results support the company's earlier communication that ATB-346 may be effective at much lower doses than previously expected and that once-daily dosing may be effective. Together, over 600 blood samples from its phase 1 human clinical trial were independently analyzed to assess the ability of ATB-346, at doses ranging from 25 milligrams to 1,000 milligrams, to inhibit the enzyme cyclooxygenase (COX). The reduction of pain and inflammation by non-steroidal anti-inflammatory drugs is attributed to their ability to inhibit COX activity.

Substantial inhibition of COX was observed at doses of ATB-346 as low as 75 milligrams, and the inhibition was maintained for 24 hours. The company continues to conduct validation studies and will report to the market as they proceed.